JNJ-88998377

Phase 1Small molecule

Johnson & Johnson

JNJ-88998377 is one of 37 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Lymphoma, Non-HodgkinActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Lymphoma, Non-HodgkinPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Lymphoma, Non-Hodgkin

NCT06470438

Clinical

Trials by Indication[1]

Lymphoma, Non-Hodgkin1 trial

A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06470438·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JNJ-88998377. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-88998377 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-88998377. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-88998377

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Lymphoma, Non-Hodgkin1 trial

References

Drug Info

Quick Facts

Related News